share_log

藥明康德：截至2023年12月31日止年度全年業績公告

WUXI APPTEC: ANNOUNCEMENT OF THE ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023

香港交易所 ·  Mar 18 20:52
Summary by Futu AI
無錫藥明康德新藥開發股份有限公司（藥明康德）公佈截至2023年12月31日止年度全年業績。報告期內，公司實現營業收入人民幣40,340.8百萬元，同比增長2.5%；實現歸母淨利潤人民幣10,690.2百萬元，同比增長21.3%。公司為全球醫藥及生命科學行業提供一體化、端到端的新藥研發和生產服務，在亞洲、歐洲、北美等地設有運營基地。藥明康德通過「CRDMO」和「CTDMO」業務模式，助力客戶提升研發效率。公司擬向全體股東每10股派發現金股息人民幣9.8336元（含稅）。此外，公司於報告期後宣佈以集中競價交易方式回購A股股份方案，並計劃於2024年6月30日前支付股息。
無錫藥明康德新藥開發股份有限公司（藥明康德）公佈截至2023年12月31日止年度全年業績。報告期內，公司實現營業收入人民幣40,340.8百萬元，同比增長2.5%；實現歸母淨利潤人民幣10,690.2百萬元，同比增長21.3%。公司為全球醫藥及生命科學行業提供一體化、端到端的新藥研發和生產服務，在亞洲、歐洲、北美等地設有運營基地。藥明康德通過「CRDMO」和「CTDMO」業務模式，助力客戶提升研發效率。公司擬向全體股東每10股派發現金股息人民幣9.8336元（含稅）。此外，公司於報告期後宣佈以集中競價交易方式回購A股股份方案，並計劃於2024年6月30日前支付股息。
Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. (Pharmaceutical Ming Kand) announces its annual results for the year ended 31 December 2023. During the reporting period, the Company achieved operating income of RMB40,340.8 million, an increase of 2.5% year-on-year; achieved a net net profit of RMB10,690.2 million, an increase of 21.3% year-on-year. THE COMPANY PROVIDES INTEGRATED, END-TO-END NEW DRUG R&D AND PRODUCTION SERVICES TO THE GLOBAL PHARMACEUTICAL AND LIFE SCIENCES INDUSTRIES, WITH OPERATING BASES IN ASIA, EUROPE, NORTH AMERICA AND MORE. Pharma Kund helps customers improve R&D efficiency through its “CRDMO” and “CTDMO” business models. The Company intends to distribute a cash dividend of RMB9.8336 (tax included) per 10 shares to all shareholders. In addition, the Company announced a plan to repurchase A shares in a centralized tender manner after the reporting period and plans to pay dividends by June 30, 2024.
Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. (Pharmaceutical Ming Kand) announces its annual results for the year ended 31 December 2023. During the reporting period, the Company achieved operating income of RMB40,340.8 million, an increase of 2.5% year-on-year; achieved a net net profit of RMB10,690.2 million, an increase of 21.3% year-on-year. THE COMPANY PROVIDES INTEGRATED, END-TO-END NEW DRUG R&D AND PRODUCTION SERVICES TO THE GLOBAL PHARMACEUTICAL AND LIFE SCIENCES INDUSTRIES, WITH OPERATING BASES IN ASIA, EUROPE, NORTH AMERICA AND MORE. Pharma Kund helps customers improve R&D efficiency through its “CRDMO” and “CTDMO” business models. The Company intends to distribute a cash dividend of RMB9.8336 (tax included) per 10 shares to all shareholders. In addition, the Company announced a plan to repurchase A shares in a centralized tender manner after the reporting period and plans to pay dividends by June 30, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.